News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in MIBC – ESMO
ESMO/LinkedIn
Feb 24, 2025, 08:09

Survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in MIBC – ESMO

ESMO (European Society for Medical Oncology) shared a post on LinkedIn:

“Additional analysis from the NIAGARA trial reported survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in both patients with muscle-invasive Bladder Cancer (MIBC) achieving a pathological complete response (pCR) and those not achieving a pCR, as well as a reduction of the risk of developing metastases and cancer-related death.

The novel data provide further support for the use of the immunotherapy-based treatment as a potential new option for cisplatin-eligible patients.

Read about the study results in the ESMO Daily Reporter.”

More posts featuring ESMO.

cancer Durvalumab ESMO ESMO Daily Reporter European Society for Medical Oncology MIBC muscle invasive bladder cancer NIAGARA OncoDaily Oncology
Special Coverage
Blog
Apr 1, 2025, 15:09
Hagop Kantarjian: Success, optimism, and challenges on the therapeutic horizon of acute myeloid leukemia
Blog
Apr 1, 2025, 15:04
Call for Papers: AI in Immune-Related Adverse Events (irAEs) - AI in Precision Oncology
Career
Apr 1, 2025, 14:57
Sharon Burk completes PhD with groundbreaking research - Sbarro Health Research Organization
Blog
Apr 1, 2025, 14:35
Douglas Flora: The messy truth behind healthcare's coming AI adoption
Blog
Apr 1, 2025, 14:31
Zainab Shinkafi-Bagudu: Processed meats and fried snacks may increase the risk of colorectal cancer
Societies
Apr 1, 2025, 14:08
Myeloma Paper of the Day, April 1st, suggested by Robert Orlowski
Blog
Apr 1, 2025, 12:54
CTOS Communications Committee: Survey to understand your engagement with social media
Science
Apr 1, 2025, 12:48
Yan Leyfman: Dual-Targeted CAR-T Therapy Shows 100% Response in MCL
Blog
Apr 1, 2025, 12:43
By 2040, the global burden of colorectal cancer is expected to rise by 63% - Digestive Cancers Europe
Blog
Apr 1, 2025, 12:34
Asya Agulnik: Breakthrough approaches needed for pediatric cancer treatment in conflict-affected regions
Blog
Apr 1, 2025, 12:18
What if 'No Response' Becomes 'No Recurrence' in Colorectal Cancer Treatment? - CancerWorld
Blog
Apr 1, 2025, 12:16
Maryam S. Yazdy: From FDA to BeiGene - Embracing a New Chapter